D-苏-五糖醇,1,5-脱水-2,3-二脱氧-3-(3,4-二羟基苯基)-1-C-(4-羟基苯基)-,(1R)- | 15215-12-0

• 分子结构分类: 有机化合物 - 木脂素、新木脂素和相关化合物
• 中文名称: D-苏-五糖醇,1,5-脱水-2,3-二脱氧-3-(3,4-二羟基苯基)-1-C-(4-羟基苯基)-,(1R)-
• 英文名称: 4-[(2R,4S,5S)-5-Hydroxy-2-(4-hydroxy-phenyl)-tetrahydro-pyran-4-yl]-benzene-1,2-diol
• 英文别名: Hydroxysugiresinol；4-[(2R,4S,5S)-5-hydroxy-2-(4-hydroxyphenyl)oxan-4-yl]benzene-1,2-diol
• CAS: 15215-12-0
• 化学式: C₁₇H₁₈O₅
• 分子量: 302.327
• InChiKey: KTBMETYOQLNVNV-IAOVAPTHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  90.2
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  D-苏-五糖醇,1,5-脱水-2,3-二脱氧-3-(3,4-二羟基苯基)-1-C-(4-羟基苯基)-,(1R)- 在 硫酸 作用下， 生成 (1S,1'S)-1-(1,2-Dihydroxyethyl)-5,6-dihydroxy-3-(4-hydroxyphenyl)-indan (Isosequirin)
  参考文献：
  名称：

  加州红木的成分：sequirin-B和sequirin-C的组成，绝对立体化学和化学

  摘要：

  从红杉心材中分离了两种新的天然酚。通过光谱和化学方法，显示一种为Sequirin-B，为（2 R，4 S，5 S）-4-（3,4-二羟基苯基）-5-羟基-2-（4-羟基苯基）四氢吡喃（I； R ＝ H）。分离出第二种，Sequirin-C，作为其甲基醚。显示为（2 S，3 S）-（E）-3-（3,4-二甲氧基苯基）-5-（4-甲氧基苯基）戊-4-烯-1,2-二醇（V）。

  DOI：

  10.1039/j39690001921

文献信息

• REPRESENTATIVE DIAGNOSTICS
  申请人：Ventana Medical Systems, Inc.

  公开号：EP3371594A1

  公开（公告）日：2018-09-12
• JPS61127763A
  申请人：——

  公开号：JPS61127763A

  公开（公告）日：1986-06-16
• PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS
  申请人：Seattle Children's Hospital (dba Seattle Children's Research Institute)

  公开号：US20200087399A1

  公开（公告）日：2020-03-19

  Aspects of the invention described herein relate to synthetic compounds that are useful for targeting and labeling tumor cells so as to facilitate recognition by binding agents including Chimeric Antigen Receptor T cells (CAR T cells), which are administered to a subject by intravenous or locoregional administration. Several compositions and methods of making and using these compositions to treat or inhibit a disease in a subject are contemplated.
• METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS
  申请人：Seattle Children's Hospital (dba Seattle Children's Research Institute)

  公开号：US20210317407A1

  公开（公告）日：2021-10-14

  Some embodiments of the methods and compositions provided herein relate to the use of hapten labeled cells to stimulate chimeric antigen receptor (CAR) T cells. In some embodiments, CAR T cells can include a CAR that specifically binds to a hapten. Some embodiments relate to the in vivo or in vitro stimulation CAR T cells by hapten labeled cells.
• [EN] REPRESENTATIVE DIAGNOSTICS<br/>[FR] DIAGNOSTIC REPRÉSENTATIF
  申请人：VENTANA MED SYST INC

  公开号：WO2017079763A1

  公开（公告）日：2017-05-11

  The disclosure generally relates to the preparation of representative samples from clinical samples, e.g., tumors (whole or in part), lymph nodes, metastases, cysts, polyps, or a combination or portion thereof, using mechanical and/or biochemical dissociation methods to homogenize intact samples or large portions thereof. The resulting homogenate provides the ability to obtain a correct representative sample despite spatial heterogeneity within the sample, increasing detection likelihood of low prevalence subclones, and is suitable for use in various diagnostic assays as well as the production of therapeutics, especially "personalized" anti-tumor vaccines or immune cell based therapies.